These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22840407)

  • 21. Automation of a phospho-STAT5 staining procedure for flow cytometry for application in drug discovery.
    Malergue F; van Agthoven A; Scifo C; Egan D; Strous GJ
    J Biomol Screen; 2015 Mar; 20(3):416-21. PubMed ID: 25325258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous Expression of
    Ho VQT; Verboom T; Rong MK; Habjan E; Bitter W; Speer A
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
    Kim W; Hendricks GL; Lee K; Mylonakis E
    Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
    Gold B; Warrier T; Nathan C
    Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
    Mukherjee R; Chandra Pal A; Banerjee M
    Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening.
    Tükenmez H; Edström I; Ummanni R; Fick SB; Sundin C; Elofsson M; Larsson C
    Sci Rep; 2019 Jan; 9(1):26. PubMed ID: 30631100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput purification platform in support of drug discovery.
    Liu M; Chen K; Christian D; Fatima T; Pissarnitski N; Streckfuss E; Zhang C; Xia L; Borges S; Shi Z; Vachal P; Tata J; Athanasopoulos J
    ACS Comb Sci; 2012 Jan; 14(1):51-9. PubMed ID: 22032344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
    Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
    J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caenorhabditis elegans-based model systems for antifungal drug discovery.
    Anastassopoulou CG; Fuchs BB; Mylonakis E
    Curr Pharm Des; 2011; 17(13):1225-33. PubMed ID: 21470110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.
    Ramón-García S; Ng C; Anderson H; Chao JD; Zheng X; Pfeifer T; Av-Gay Y; Roberge M; Thompson CJ
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3861-9. PubMed ID: 21576426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a web-based tool for automated processing and cataloging of a unique combinatorial drug screen.
    Dalecki AG; Wolschendorf F
    J Microbiol Methods; 2016 Jul; 126():30-4. PubMed ID: 27117032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation.
    Rihel J; Prober DA; Arvanites A; Lam K; Zimmerman S; Jang S; Haggarty SJ; Kokel D; Rubin LL; Peterson RT; Schier AF
    Science; 2010 Jan; 327(5963):348-51. PubMed ID: 20075256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening and zebrafish models in tandem, for drug discovery and development.
    Hernández-Silva D; Alcaraz-Pérez F; Pérez-Sánchez H; Cayuela ML
    Expert Opin Drug Discov; 2023; 18(8):903-915. PubMed ID: 36383405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis.
    Forbes L; Ebsworth-Mojica K; DiDone L; Li SG; Freundlich JS; Connell N; Dunman PM; Krysan DJ
    PLoS One; 2015; 10(6):e0129234. PubMed ID: 26098625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assay development for identifying inhibitors of the mycobacterial FadD32 activity.
    Galandrin S; Guillet V; Rane RS; Léger M; N R; Eynard N; Das K; Balganesh TS; Mourey L; Daffé M; Marrakchi H
    J Biomol Screen; 2013 Jun; 18(5):576-87. PubMed ID: 23364516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in zebrafish chemical screening technologies.
    Mathias JR; Saxena MT; Mumm JS
    Future Med Chem; 2012 Sep; 4(14):1811-22. PubMed ID: 23043478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.